TY - JOUR
T1 - The Multi-Center Morphometric Mammary Carcinoma Project (MMMCP) in The Netherlands
T2 - value of morphometrically assessed proliferation and differentiation.
AU - Baak, J. P.
AU - van Diest, P. J.
AU - Benraadt, T.
AU - Matze-Cok, E.
AU - Brugghe, J.
AU - Schuurmans, L. T.
AU - Littooy, J. J.
PY - 1993
Y1 - 1993
N2 - The Multi-Center Morphometric Mammary Carcinoma Project (MMMCP) was set up to investigate the reproducibility and prognostic value of routine assessments of morphometric parameters [mean nuclear area (MNA), mitotic activity index (MAI), and multivariate prognostic index (MPI)] and cytometric features (DNA ploidy and index, % S-phase cells, as well as other cell cycle data) in comparison with classical prognostic parameters and steroid receptors. Thirty-four hospitals in six geographic regions participated. In 1988-1989, 3427 patients entered the study and morphometric assessments were made. An interim (1993) survival analysis indicated that MAI, MNA, and MPI are the strongest predictors of outcome. A Phase III randomized prospective multi-center trial [Premenopausal Morphometric Intervention Study (PREMIS)] using these endpoints was initiated in Europe to evaluate adjuvant [cyclophosphamide, methotrexate and 5-fluorouracil (CMF)] chemotherapy versus observation in morphometrically high risk (i.e., MAI > 10), premenopausal, lymph node negative (LN-) breast cancer patients.
AB - The Multi-Center Morphometric Mammary Carcinoma Project (MMMCP) was set up to investigate the reproducibility and prognostic value of routine assessments of morphometric parameters [mean nuclear area (MNA), mitotic activity index (MAI), and multivariate prognostic index (MPI)] and cytometric features (DNA ploidy and index, % S-phase cells, as well as other cell cycle data) in comparison with classical prognostic parameters and steroid receptors. Thirty-four hospitals in six geographic regions participated. In 1988-1989, 3427 patients entered the study and morphometric assessments were made. An interim (1993) survival analysis indicated that MAI, MNA, and MPI are the strongest predictors of outcome. A Phase III randomized prospective multi-center trial [Premenopausal Morphometric Intervention Study (PREMIS)] using these endpoints was initiated in Europe to evaluate adjuvant [cyclophosphamide, methotrexate and 5-fluorouracil (CMF)] chemotherapy versus observation in morphometrically high risk (i.e., MAI > 10), premenopausal, lymph node negative (LN-) breast cancer patients.
UR - http://www.scopus.com/inward/record.url?scp=0027865541&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0027865541&partnerID=8YFLogxK
M3 - Article
C2 - 8007702
AN - SCOPUS:0027865541
SN - 0733-1959
VL - 17 G
SP - 220
EP - 225
JO - Journal of cellular biochemistry. Supplement
JF - Journal of cellular biochemistry. Supplement
ER -